Program
Ascorbic Acid
Also written as “Vitamin C”, “PLENVU®” and “Ascorbic acid ophthalmic solution 5%”.
Its studies are mostly in Respiratory Tract Infections · Corneal Endothelial Cell Loss · Neuralgia · Pain · Carcinoma, Basal Cell, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 30 open or running | phase 4since Apr 7, 2011 | Apr 7, 2011 | none ahead |
| Caravel Oculus Pty | 11 open or running | phase 2since Jul 1, 2026 | Jul 1, 2026 | Jan 2027phase 2 · NCT07694375 |
| Center for Biomedical Research | 10 open or running | early phase 1since Feb 19, 2020 | Feb 19, 2020 | none ahead |
| LadeRx | 11 open or running | phase 1since May 20, 2024 | May 20, 2024 | none ahead |
| Lindenhofgruppe | 10 open or running | phase 4since Jul 10, 2020 | Jul 10, 2020 | none ahead |
| McGuff Pharmaceuticals | 10 open or running | phase 1since Aug 24, 2015 | Aug 24, 2015 | none ahead |
| Pascoe Pharmazeutische Praeparate | 10 open or running | phase 2since Sep 27, 2022 | Sep 27, 2022 | none ahead |
| Spherium Biomed | 10 open or running | phase 2since Nov 10, 2015 | Nov 10, 2015 | none ahead |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2011First study: phase 4 study in Influenza, HumanNew to GlaxoSmithKlineGlaxoSmithKline · NCT01332578 · 25 enrolled · United Kingdom
- Aug 24, 2015McGuff Pharmaceuticals's first study: phase 1 study in PharmacokineticsNew to McGuff PharmaceuticalsMcGuff Pharmaceuticals · NCT02534753 · 8 enrolled · United States
- Nov 10, 2015Spherium Biomed's first study: phase 2 study in Temporomandibular Joint DisordersNew to Spherium BiomedSpherium Biomed · NCT02602483 · 96 enrolled · Spain
- Feb 1, 20162 phase 3 studies in Respiratory Tract InfectionsGlaxoSmithKline · NCT02730364, NCT02678234
- Feb 19, 2020Center for Biomedical Research's first study: early phase 1 study in Carcinoma, Basal CellNew to Center for Biomedical ResearchCenter for Biomedical Research · NCT04279535 · 25 enrolled · United States
- Jul 10, 2020Lindenhofgruppe's first study: phase 4 study in PainNew to LindenhofgruppeLindenhofgruppe · NCT04472000 · 46 enrolled · Switzerland
- Sep 27, 2022Pascoe Pharmazeutische Praeparate's first study: phase 2 study in NeuralgiaNew to Pascoe Pharmazeutische PraeparatePascoe Pharmazeutische Praeparate · NCT05561257 · 12 enrolled · Germany
- May 20, 2024LadeRx's first study: phase 1 study in SafetyNew to LadeRxLadeRx · NCT06433791 · 12 planned · United States
- Jul 1, 2026Caravel Oculus Pty's first study: phase 2 study in Corneal Endothelial Cell LossNew to Caravel Oculus PtyCaravel Oculus Pty · NCT07694375 · 200 planned · Australia
Ahead
- Jan 2027Primary completion: phase 2 study in Corneal Endothelial Cell LossCaravel Oculus Pty · NCT07694375
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07694375Corneal Endothelial Cell Loss · Australia | 2 | Recruiting | Caravel Oculus Pty | Jan 2027 | 200 |
| NCT06433791Safety · United States | 1 | By invitation | LadeRx | May 17, 2025 | 12 |
| NCT05561257Neuralgia · Germany | 2 | Terminated | Pascoe Pharmazeutische Praeparate | Feb 28, 2024 | 12 |
| NCT04472000Pain · Switzerland | 4 | Terminated | Lindenhofgruppe | May 16, 2023 | 46 |
| NCT04279535Carcinoma, Basal Cell · United States | Early 1 | Completed | Center for Biomedical Research | Mar 1, 2019 | 25 |
| NCT02678234Respiratory Tract Infections | 3 | Withdrawn | GlaxoSmithKline | Apr 1, 2017 | 0 |
| NCT02730364Respiratory Tract Infections | 3 | Withdrawn | GlaxoSmithKline | Apr 1, 2017 | 0 |
| NCT02602483Temporomandibular Joint Disorders · Spain | 2 | Completed | Spherium Biomed | Dec 2016 | 96 |
| NCT02534753Pharmacokinetics · United States | 1 | Completed | McGuff Pharmaceuticals | Nov 2015 | 8 |
| NCT01332578Influenza, Human · United Kingdom | 4 | Completed | GlaxoSmithKline | Jun 2011 | 25 |
How it is read
Names in the registry
- “Vitamin C”, 2 entries
- “Ascorbic Acid”, 2 entries
- “PLENVU®”, 1 entry
- “Ascorbic acid ophthalmic solution 5%”, 1 entry
- “Ascorbate-Meglumine”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Tract Infections, 2 studies
- Corneal Endothelial Cell Loss, 1 study
- Neuralgia, 1 study
- Pain, 1 study
- Carcinoma, Basal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.